Prevent rising uric acid levels

In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia

THE POWER TO PREVENT RISING URIC
ACID LEVELS IS IN YOUR HANDS

Explore Clinical Data

Prevent rising uric acid levels

In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia

THE POWER TO PREVENT RISING URIC
ACID LEVELS IS IN YOUR HANDS

Explore Clinical Data

In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more patients (87%, n=92) vs allopurinol (66%, n=91) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001) (primary endpoint).1

Mechanism of action

MOA

mechanism of action

See how ELITEK functions differently than allopurinol

EXPLORE ELITEK MOA

Identify patients at risk

IDENTIFY

patients at risk

Find out what your peers are saying about patients at higher risk for TLS

SEE TLS RISK FACTORS

Request a rep

REQUEST

a rep

Get in contact with an ELITEK representative

CONTACT A REP

Mechanism of action

MOA

mechanism of action

See how ELITEK functions differently than allopurinol

EXPLORE ELITEK MOA
Identify patients at risk

IDENTIFY

patients at risk

Find out what your peers are saying about patients at higher risk for TLS

SEE TLS RISK FACTORS
Request a rep

REQUEST

a rep

Get in contact with an ELITEK representative

CONTACT A REP
CareASSIST<sup>®</sup> Patient Support by Sanofi Genzyme. CareASSIST offers access support for eligible patients prescribed ELITEK
CareASSIST<sup>®</sup> ELITEK<sup>®</sup> (rasburicase)
CareASSIST<sup>®</sup> Patient Support by Sanofi Genzyme. CareASSIST offers access support for eligible patients prescribed ELITEK
CareASSIST<sup>®</sup> ELITEK<sup>®</sup> (rasburicase)

CAREASSIST PROGRAM

Find resources and support for eligible patients

Access and support

access and reimbursement

Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals.

Financial assistance

financial assistance

CareASSIST offers programs and services that can help eligible patients with the cost of ELITEK.

Resource support

resource support

Information on independent support services for patients and caregivers, as well as product ordering and replacement information.

LEARN ABOUT CAREASSIST
LEARN ABOUT CAREASSIST

Reference: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS

ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose

Please see full Prescribing Information, including Boxed WARNING.

MAT-US-2020029-v1.0-01/2021
Last Updated: January 2021-01-01YYYY